- Record: found
- Abstract: found
- Article: found
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
Paula Ghaneh ,
Daniel Palmer ,
Silvia Cicconi ,
Richard Jackson ,
Christopher Michael Halloran ,
Charlotte Rawcliffe ,
Rajaram Sripadam ,
Somnath Mukherjee ,
Zahir Soonawalla ,
Jonathan Wadsley ,
Ahmed Al-Mukhtar ,
Euan Dickson ,
Janet Graham ,
Long Jiao ,
Harpreet S Wasan ,
Iain S Tait ,
Andreas Prachalias ,
Paul Ross ,
Juan W Valle ,
Derek A O'Reilly ,
Bilal Al-Sarireh ,
Sarah Gwynne ,
Irfan Ahmed ,
Kate Connolly ,
Kein-Long Yim ,
David Cunningham ,
Thomas Armstrong ,
Caroline Archer ,
Keith Roberts ,
Yuk Ting Ma ,
Christoph Springfeld ,
Christine Tjaden ,
Thilo Hackert ,
Markus W Büchler ,
John P Neoptolemos
December 2022
December 2022
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively
low resection rates and poor survival despite the use of adjuvant chemotherapy. The
aim of our study was to establish the feasibility and efficacy of three different
types of short-course neoadjuvant therapy compared with immediate surgery.